DWM
ABBV icon

Doyle Wealth Management’s AbbVie ABBV Stock Holding History

Doyle Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$4.66M Buy
34,715
+599
+2% +$86K 0.4% 60
2022
Q2 		$5.22M Sell
34,116
-1,122
-3% -$171K 0.42% 63
2022
Q1 		$5.71M Buy
35,238
+1,293
+4% +$188K 0.41% 64
2021
Q4 		$4.6M Buy
33,945
+1,519
+5% +$179K 0.33% 65
2021
Q3 		$3.5M Buy
32,426
+2,481
+8% +$283K 0.28% 69
2021
Q2 		$3.37M Buy
29,945
+2,619
+10% +$295K 0.28% 70
2021
Q1 		$2.96M Buy
27,326
+1,586
+6% +$170K 0.28% 68
2020
Q4 		$2.76M Buy
25,740
+19,713
+327% +$1.89M 0.28% 68
2020
Q3 		$528K Buy
6,027
+497
+9% +$46.8K 0.06% 124
2020
Q2 		$543K Sell
5,530
-228
-4% -$20.1K 0.07% 111
2020
Q1 		$439K Buy
5,758
+810
+16% +$69K 0.07% 112
2019
Q4 		$438K Buy
4,948
+108
+2% +$8.97K 0.05% 133
2019
Q3 		$366K Buy
4,840
+1,625
+51% +$111K 0.05% 140
2019
Q2 		$234K Buy
3,215
+6
+0.2% +$472 0.03% 177
2019
Q1 		$249K Sell
3,209
-3,627
-53% -$297K 0.04% 167
2018
Q4 		$630K Buy
6,836
+779
+13% +$68.5K 0.11% 87
2018
Q3 		$573K Sell
6,057
-61,757
-91% -$5.86M 0.09% 101
2018
Q2 		$6.28M Sell
67,814
-1,263
-2% -$123K 1.04% 39
2018
Q1 		$6.54M Sell
69,077
-331
-0.5% -$36.4K 1.1% 35
2017
Q4 		$6.71M Sell
69,408
-2,091
-3% -$197K 1.13% 34
2017
Q3 		$6.35M Sell
71,499
-52,317
-42% -$3.98M 1.11% 36
2017
Q2 		$8.98M Buy
123,816
+3,427
+3% +$230K 1.66% 25
2017
Q1 		$7.84M Buy
+120,389
New +$7.57M 1.6% 23

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Doyle Wealth Management's ABBV Position: Q3 2022 in Review

Doyle Wealth Management increased its AbbVie (ABBV) stake by 1.8% in Q3 2022, buying an estimated $86K and bringing the position to 34,715 shares worth $4.66M. The position accounts for 0.4% of the portfolio, ranked #60.

Doyle Wealth Management first reported a position in ABBV in Q1 2017 and has held it in 23 quarters since. The position peaked at $8.98M in Q2 2017. 2,968 funds tracked by Wall St. Rank hold ABBV as of Q3 2022.

  • Doyle Wealth Management held 34,715 shares of AbbVie worth $4.66M as of Q3 2022.
  • Doyle Wealth Management bought 599 AbbVie shares in Q3 2022, an estimated $86K.
  • AbbVie made up 0.4% of Doyle Wealth Management's portfolio in Q3 2022, its #60 holding.
  • Doyle Wealth Management first reported a position in AbbVie in Q1 2017 and has held it in 23 quarters since.
  • Doyle Wealth Management's AbbVie position peaked at $8.98M in Q2 2017.
  • 2,968 funds tracked by Wall St. Rank held AbbVie as of Q3 2022.

Based on Doyle Wealth Management's 13F filing for Q3 2022, filed 15 Nov 2022.